The Danish drugmaker Novo Nordisk have released positive statistics regarding their new potential diabetes drug, Liraglutide. In response to the news, Novo shares leapt by 6 per cent in afternoon trading yesterday.
According to Novo, one of the foremost diabetic drug companies in the world, Phase III clinical trials of the drug showed that it is more effective in controlling blood glucose than both lantus and a placebo.
Furthermore, patients taking the drug were found to lose weight over a 26-week period. This positive side effect is likely to be of interest to diabetics – losing weight is a key feature of controlling diabetes successfully.
The drug could become a blockbuster for Novo Nordisk if it receives approval from the Food and Drug Administration and all relevant European bodies.
Novo Nordisk release positive data on diabetes drug
Fri, 22 Jun 2007
